Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Prepaid Assets (2016 - 2025)

Protalix BioTherapeutics has reported Prepaid Assets over the past 12 years, most recently at $1.1 million for Q4 2025.

  • Quarterly results put Prepaid Assets at $1.1 million for Q4 2025, up 125.8% from a year ago — trailing twelve months through Dec 2025 was $1.1 million (up 125.8% YoY), and the annual figure for FY2025 was $1.1 million, up 125.8%.
  • Prepaid Assets for Q4 2025 was $1.1 million at Protalix BioTherapeutics, down from $1.5 million in the prior quarter.
  • Over the last five years, Prepaid Assets for PLX hit a ceiling of $3.0 million in Q2 2021 and a floor of $500000.0 in Q4 2024.
  • Median Prepaid Assets over the past 5 years was $1.4 million (2022), compared with a mean of $1.4 million.
  • Biggest five-year swings in Prepaid Assets: tumbled 56.82% in 2021 and later surged 125.8% in 2025.
  • Protalix BioTherapeutics' Prepaid Assets stood at $905000.0 in 2021, then skyrocketed by 44.75% to $1.3 million in 2022, then dropped by 19.47% to $1.1 million in 2023, then tumbled by 52.61% to $500000.0 in 2024, then surged by 125.8% to $1.1 million in 2025.
  • The last three reported values for Prepaid Assets were $1.1 million (Q4 2025), $1.5 million (Q3 2025), and $1.5 million (Q2 2025) per Business Quant data.